Biodesix Finds $8.3M In Series E Funding
Boulder-based molecular diagnostics provider Biodesix said this morning that it has raised $8.3M in a Series E equity funding round. The company said the funding was split between 44.3M in new capital, plus $4M in conversion of a convertible note. The funding came from the company's existing investors, who were not named by the company. Biodesix is developing diagnostic testing technology, with a first focus on advanced non-small cell lung cancer (NSCLC). The firm is led by David Brunel.
posted on Monday, December 2, 2013 (Link to more information)
Related companies:
BIODESIX INC
Related stories:
> Biodesix Raises $12M More In Series E Funding
> Biodesix Brings Series E To $14.4M
> Biodesix Raises $8.8M More
> Biodesix Scores $7.1M For Lung Cancer Tests
> MasteryConnect Finds $4.5M In Series C Funding
Techrockies.com Home